Novel ultrasensitive detection device for early Sepsis diagnosis

Project Information

IVD4Sepsis

Grant agreement ID: 836153

DOI

10.3030/836153

Project closed

EC signature date 21 December 2018

Start date 1 January 2019

End date 30 April 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

MECWINS SA
Spain

Periodic Reporting for period 1 - IVD4Sepsis (Novel ultrasensitive detection device for early Sepsis diagnosis)

Reporting period: 2019-01-01 to 2019-04-30

Summary of the context and overall objectives of the project

Sepsis, defined as an extremely complex syndrome induced by infection, is a major public health concern according to the data of incidence, mortality and hospital costs reported. It remains a major cause of human disability and death throughout the world: it affects 30 million people worldwide every year (25% of sepsis patients die) and is the largest killer of children (around 82.000 every day; a death every three to four seconds). Accurate and early detection of sepsis remains a challenge.
Through the IVD4Sepsis project, Mecwins’ main objective is to bring to the market its proprietary AVAC technology as a reference technology for the detection of cytokine biomarkers, first for early sepsis diagnosis but with the ambition of later positioning it as the reference technology for a wide range of other clinical applications. IVD4Sepsis project will contribute to improve Sepsis diagnosis and therefore the survival rate of patients.
At the end of the project, IVD4Sepsis technology will meet the requirements of the sector and Mecwins will have the manufacturing capacity to cover the initial market penetration, creating important competitive technological and market advantages over future competitors, becoming a worldwide referent in offering analytical solutions in the diagnostic sector, first in the specific field of sepsis, but later extended to other critical illness fields such as oncology, cardiovascular diseases, autoimmune diseases and other infectious diseases than sepsis, such as HIV, meningitis.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The objective of this Feasibility Study was to assess the feasibility of IVD4Sepsis project (Phase2) objectives, and to update the business innovation plan. As result of the Feasibility Study, a more detailed and reliable business innovation project aligned to MECWINS’s corporate strategy and with the customer needs has been elaborated.
Technical and financial viability of IVD4Sepsis has been validated:
- MECWINS's technology remains as the most feasible and effective beyond state of the art technologies currently available in the market.
- Nowadays, IVD4Sepsis does not have a critical competitor because a similar technology that offers such an advantageous performance has not been developed.
- As per result of IVD4Sepsis background and foreground IPR assessment, freedom to operate has been validated.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

IVD4Sepsis is really a high value proposal because is based on innovative technology but focused totally to respond the needs of the heath sector. Its technical specifications and characteristics have been designed specially to improve the current methods and instruments used nowadays having important impacts thanks to IVD4Sepsis accurate, fast, cost and simplicity.